Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases ...

Related Keywords

United States ,South San Francisco ,California ,San Diego ,Pratik Multani ,Jacobm Chacko ,Dominic Piscitelli ,Securities Exchange ,European Society Of Medical Oncology ,Linkedin ,Nasdaq ,Exchange Commission ,Pharmaceuticals Inc ,Globenewswire Inc ,Medical Oncology ,Escalation Data ,Pharmacokinetic Analysis ,Overcoming Resistance ,San Francisco ,Securities Act ,Securities Exchange Act ,Chief Financial ,Markets ,